236 results
Type of content
News Remove News filter
Categories
Human Remove Human filter
Responsible body
PRAC Remove PRAC filter
-
List item
News: Meeting highlights from the Pharmacovigilance Risk Assessment Committee (PRAC) 10 - 13 January 2022
PRAC, Last updated: 14/01/2022 -
List item
News: EMA receives application for conditional marketing authorisation for Paxlovid (PF-07321332 and ritonavir) for treating patients with COVID-19
CHMP, PRAC, Last updated: 10/01/2022 -
List item
News: Meeting highlights from the Pharmacovigilance Risk Assessment Committee (PRAC) 29 November - 2 December 2021
PRAC, Last updated: 03/12/2021 -
List item
News: EMA receives application for marketing authorisation for Xevudy (sotrovimab) for treating patients with COVID-19
CHMP, PDCO, PRAC, Last updated: 18/11/2021 -
List item
News: Meeting highlights from the Pharmacovigilance Risk Assessment Committee (PRAC) 25-28 October 2021
PRAC, Last updated: 29/10/2021 -
List item
News: EMA receives application for marketing authorisation for Ronapreve (casirivimab / imdevimab) for treatment and prevention of COVID-19
CHMP, PDCO, PRAC, Last updated: 11/10/2021 -
List item
News: EMA receives application for marketing authorisation for Regkirona (regdanvimab) for treating patients with COVID-19
CHMP, PDCO, PRAC, Last updated: 04/10/2021 -
List item
News: EMA starts review of meningioma risk with nomegestrol- and chlormadinone-containing medicines
PRAC, Last updated: 01/10/2021 -
List item
News: Meeting highlights from the Pharmacovigilance Risk Assessment Committee (PRAC) 27-30 September 2021
PRAC, Last updated: 01/10/2021 -
List item
News: Call for expressions of interest for civil society representatives to participate in work of EMA
PRAC, Last updated: 27/10/2021 -
List item
News: Meeting highlights from the Pharmacovigilance Risk Assessment Committee (PRAC) 30 August – 2 September 2021
PRAC, Last updated: 17/09/2021 -
List item
News: Meeting highlights from the Pharmacovigilance Risk Assessment Committee (PRAC) 5 August 2021
PRAC, Last updated: 06/08/2021 -
List item
News: COVID-19 Vaccine Janssen: Guillain-Barré syndrome listed as a very rare side effect
PRAC, Last updated: 22/07/2021 -
List item
News: Meeting highlights from the Pharmacovigilance Risk Assessment Committee (PRAC) 5-8 July 2021
PRAC, Last updated: 09/07/2021 -
List item
News: EMA finds no evidence linking viral vector in Zynteglo to blood cancer
PRAC, Last updated: 09/07/2021 -
List item
News: Comirnaty and Spikevax: possible link to very rare cases of myocarditis and pericarditis
PRAC, Last updated: 09/07/2021 -
List item
News: EMA advises against use of COVID-19 Vaccine Janssen in people with history of capillary leak syndrome
PRAC, Last updated: 09/07/2021 -
List item
News: Meeting highlights from the Pharmacovigilance Risk Assessment Committee (PRAC) 7-10 June 2021
PRAC, Last updated: 11/06/2021 -
List item
News: COVID-19 vaccines: update on ongoing evaluation of myocarditis and pericarditis
PRAC, Last updated: 11/06/2021 -
List item
News: Vaxzevria: EMA advises against use in people with history of capillary leak syndrome
PRAC, Last updated: 11/06/2021 -
List item
News: Meeting highlights from the Pharmacovigilance Risk Assessment Committee (PRAC) 3-6 May 2021
PRAC, Last updated: 07/05/2021 -
List item
News: COVID-19 Vaccine Janssen: EMA finds possible link to very rare cases of unusual blood clots with low blood platelets
PRAC, Last updated: 20/04/2021 -
List item
News: COVID-19 Vaccine Janssen: assessment of very rare cases of unusual blood clots with low platelets continues
PRAC, Last updated: 14/04/2021 -
List item
News: Meeting highlights from the Pharmacovigilance Risk Assessment Committee (PRAC) 6-9 April 2021
PRAC, Last updated: 09/04/2021 -
List item
News: AstraZeneca’s COVID-19 vaccine: EMA finds possible link to very rare cases of unusual blood clots with low blood platelets
PRAC, Last updated: 07/04/2021